Dr. Yamo Deniz to Join Cytos Biotechnology's Board of Directors
Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013
Research and Markets: PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players
Research and Markets: Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis
Myrtle S. Potter Appointed to Rite Aid Board of Directors
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla® in the European Union
Netskope Ranks CrashPlan #3 Out of 2,600 Cloud Applications Evaluated for Enterprise-Readiness
Sixth Annual Biotech Showcase™ Returns to San Francisco January 13–15
Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...